Caricamento...
Drugging the Undruggable: Advances on RAS Targeting in Cancer
Around 20% of all malignancies harbour activating mutations in RAS isoforms. Despite this, there is a deficiency of RAS-targeting agents licensed for therapeutic use. The picomolar affinity of RAS for GTP, and the lack of suitable pockets for high-affinity small-molecule binding, precluded effective...
Salvato in:
| Pubblicato in: | Genes (Basel) |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
MDPI
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8228461/ https://ncbi.nlm.nih.gov/pubmed/34200676 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/genes12060899 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|